Credit Suisse’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-89,490
| Closed | -$376K | – | 3335 |
|
|
2023
Q1 | $376K | Buy |
89,490
+15,357
| +21% | +$79.7K | ﹤0.01% | 2903 |
|
|
2022
Q4 | $446K | Buy |
74,133
+73,561
| +12,860% | +$401K | ﹤0.01% | 2858 |
|
|
2022
Q3 | $3K | Buy |
572
+526
| +1,143% | +$3.28K | ﹤0.01% | 3686 |
|
|
2022
Q2 | $0 | Buy |
+46
| New | +$236 | ﹤0.01% | 4619 |
|
|
2021
Q2 | – | Sell |
-14,117
| Closed | -$41K | – | 4776 |
|
|
2021
Q1 | $41K | Buy |
+14,117
| New | +$46.1K | ﹤0.01% | 4239 |
|
|
2019
Q3 | – | Sell |
-12,549
| Closed | -$11K | – | 4385 |
|
|
2019
Q2 | $11K | Sell |
12,549
-13,761
| -52% | -$12.7K | ﹤0.01% | 4058 |
|
|
2019
Q1 | $26K | Buy |
+26,310
| New | +$27.7K | ﹤0.01% | 3936 |
|
|
2018
Q3 | – | Sell |
-22,233
| Closed | -$110K | – | 4168 |
|
|
2018
Q2 | $110K | Buy |
22,233
+11,143
| +100% | +$48.8K | ﹤0.01% | 3828 |
|
|
2018
Q1 | $43K | Buy |
+11,090
| New | +$39K | ﹤0.01% | 3893 |
|
|
2016
Q4 | – | Sell |
-4,419
| Closed | -$16K | – | 4370 |
|
|
2016
Q3 | $16K | Sell |
4,419
-41,960
| -90% | -$153K | ﹤0.01% | 4060 |
|
|
2016
Q2 | $158K | Buy |
46,379
+24,509
| +112% | +$112K | ﹤0.01% | 3952 |
|
|
2016
Q1 | $117K | Buy |
21,870
+10,179
| +87% | +$81.3K | ﹤0.01% | 3805 |
|
|
2015
Q4 | $144K | Buy |
11,691
+1,874
| +19% | +$25K | ﹤0.01% | 4006 |
|
|
2015
Q3 | $143K | Sell |
9,817
-1,794
| -15% | -$31K | ﹤0.01% | 4040 |
|
|
2015
Q2 | $226K | Buy |
11,611
+2,633
| +29% | +$50.8K | ﹤0.01% | 4164 |
|
|
2015
Q1 | $163K | Sell |
8,978
-1,016
| -10% | -$22.9K | ﹤0.01% | 4136 |
|
|
2014
Q4 | $236K | Buy |
9,994
+2,300
| +30% | +$53.2K | ﹤0.01% | 4198 |
|
|
2014
Q3 | $186K | Sell |
7,694
-9,707
| -56% | -$252K | ﹤0.01% | 4165 |
|
|
2014
Q2 | $489K | Sell |
17,401
-81
| -0.5% | -$2.43K | ﹤0.01% | 3838 |
|
|
2014
Q1 | $594K | Sell |
17,482
-29,603
| -63% | -$1.01M | ﹤0.01% | 3578 |
|
|
2013
Q4 | $899K | Buy |
47,085
+1,418
| +3% | +$25.8K | ﹤0.01% | 3362 |
|
|
2013
Q3 | $740K | Buy |
45,667
+32,328
| +242% | +$375K | ﹤0.01% | 3197 |
|
|
2013
Q2 | $140K | Buy |
+13,339
| New | +$156K | ﹤0.01% | 3950 |
|
Other funds holding CTIC
Credit Suisse's CTIC Position: Q2 2023 in Review
Credit Suisse sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 89,490 shares — an estimated $376K sold.
Credit Suisse first reported a position in CTIC in Q2 2013 and held it in 23 quarters. The position peaked at $899K in Q4 2013. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Credit Suisse reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Credit Suisse sold 89,490 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $376K.
- Credit Suisse first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 23 quarters.
- Credit Suisse's CTI BioPharma Corp. (DE) Common Stock position peaked at $899K in Q4 2013.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.